Summary:
- The article discusses the emergence of novel non-opioid pain management therapies and pharmaceuticals, specifically highlighting innovations in addressing chronic pain.
- It examines the regulatory hurdles and bureaucratic challenges imposed by the FDA and other government bodies that may delay the clinical implementation and accessibility of these scientific advancements.